Dashboard
Discussions
Watchlists
Collections
Tools
More
Events
𝛼
SK
or Search
SIGN UP
SIGN IN
ENTITY
SAI Life Sciences (SAILS12 IN)
Watchlist
32
Analysis
Health Care
•
India
SAI Life Sciences Limited develops pharmaceuticals. The Company focuses on drug and active ingredient discovery, development, and manufacturing. SAI Life Sciences manages research facilities worldwide.
more
Watchlist
All
Insights
Primers
Broker
Sponsored
Syndicated
Podcast
Buy side
Refresh
Focused
Suggested
bullish
•
Anthem Biosciences
•
11 Jul 2025 13:15
Anthem Biosciences IPO - D&M Vertical Continues to Drive CRDMO Business
Anthem Biosciences is looking to raise about US$397m in its India IPO. In this note, we will talk about the RHP updates.
Akshat Shah
Follow
727 Views
Share
bullish
•
Kioxia Holdings
•
16 Jun 2025 08:08
ECM Weekly (16 June 2025) - Haitian, Sanhua, Kitazato, Primo, Kioxia, Xtalpi, Horizon, Keymed, Wuxi
Aequitas Research's weekly update on the IPOs, placements, lockup expiry and other ECM linked events that were covered by the team over the past week.
Sumeet Singh
Follow
655 Views
Share
bullish
•
Divi's Laboratories
•
12 Jun 2025 23:13
Divi's Laboratories (DIVI IN): Double-Digit Growth and Margin Improvement to Continue
Divi's Laboratories finished FY25 strong. Moving ahead, the company is looking to maintain double-digit revenue growth. This compares favorably...
Tina Banerjee
Follow
771 Views
Share
bearish
•
Niva Bupa Health Insurance
•
02 Jun 2025 10:18
Niva Bupa Health Insurance IPO Lockup-Bunch of PE Investors Could Pare Around US$500m Worth of Stock
PE fund True North (via Fettle Tone) and Niva Bupa's MD and CEO, Krishnan Ramachandran have launched a INR10.8bn (US$126m) block of 132m shares or...
Akshat Shah
Follow
699 Views
Share
bearish
•
Sagility
•
26 May 2025 22:46
Sagility India IPO Lockup - US$1.5bn Lockup Release; PE Promoter Will Have to Trim for Free-Float
Sagility B.V. plans to offload up to 15.02% stake in Sagility India via block deals worth INR26.7bn (US$314.7m). The secondary share sale is priced...
Akshat Shah
Follow
1.1k Views
Share
First
Previous
1
2
3
4
5
6
Next
Last
For Institutional Investors and Financial Services
For Corporate IR and Strategy
For Private Wealth Intermediaries
Pricing
How Smartkarma Compares
Who We Are
Careers
FAQs
Research Provider Solutions
Syndicate your Publications
Compliance
Terms of Use
Privacy Policy
Press Kit
RSS Feeds
Request a Free Trial
Avail a Transition Account
Guest Posts on Smartkarma
Other Enquiries
Join TL;DR Community
Free Weekly Newsletters
Copyright © 2022 Smartkarma Innovations Pte Ltd. All Rights Reserved. v3.70.4
x